Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6646 to 6660 of 7680 results

  1. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Evidence summary
    Published
    13 July 2012

  2. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Evidence summary
    Published
    18 January 2013

  3. Acute diarrhoea in adults: racecadotril (ESNM11)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    12 March 2013

  4. Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    12 March 2013

  5. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    4 April 2017

  6. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

    This evidence summary has been updated and replaced by NICE guideline NG101.

    Evidence summary
    Published
    25 July 2017

  7. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    3 May 2018

  8. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    22 December 2016

  9. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Evidence summary
    Published
    2 December 2020

  10. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Evidence summary
    Published
    19 March 2013

  11. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

    Evidence summary
    Published
    9 April 2013

  12. Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

    This evidence summary has been updated and replaced by NICE guideline CG61.

    Evidence summary
    Published
    9 April 2013

  13. Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    16 April 2013

  14. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Evidence summary
    Published
    23 May 2013

  15. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    7 May 2013